
NICE approval of Casgevy: a new era for sickle cell disease treatments in the UK
In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world’s first clustered regularly interspaced short palindromic …